Literature DB >> 16447202

Warm ischemia-reperfusion injury is decreased by tacrolimus in steatotic rat liver.

Marina Laurens1, Gitana Scozzari, Damiano Patrono, Marie-Christine St-Paul, Jean Gugenheim, Pierre-Michel Huet, Dominique Crenesse.   

Abstract

Ischemia-reperfusion (I-R) injury is poorly tolerated by fatty livers, most probably secondary to reduced cellular adenosine triphosphate (ATP) levels. We investigated the effectiveness of tacrolimus pretreatment on fatty liver I-R injury in obese Zucker rats. Tacrolimus (0.3 mg/kg, intravenously) was injected 24 hours before a 75-minute ischemic period and rats were sacrificed 6 hours later. Tacrolimus modified the response to I-R observed in obese Zucker rats, when compared to nontreated obese rats: a significant reduction in hepatocyte necrosis was associated with a significant increase in hepatocyte apoptosis. In addition, cell necrosis and apoptosis were significantly and inversely correlated in lean nontreated and treated obese Zucker rats following I-R. Tacrolimus also significantly increased the hepatic ATP levels, reduced in nontreated obese rats, toward values found in lean Zucker rat livers. This protective effect of tacrolimus was further confirmed in vivo by a significantly improved survival following pretreatment with tacrolimus, 24 hours prior to ischemia. In conclusion, in obese Zucker rat livers, tacrolimus pretreatment reversed the I-R injury toward the one found in lean Zucker rats. The correlations between ATP levels and the opposite changes in necrosis and apoptotic pathways strongly suggest a cause-effect relationship between tacrolimus and changes in ATP levels. Copyright 2006 AASLD

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16447202     DOI: 10.1002/lt.20585

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

Review 1.  Liver defatting: an alternative approach to enable steatotic liver transplantation.

Authors:  N I Nativ; T J Maguire; G Yarmush; D L Brasaemle; S D Henry; J V Guarrera; F Berthiaume; M L Yarmush
Journal:  Am J Transplant       Date:  2012-10-11       Impact factor: 8.086

2.  Elevated sensitivity of macrosteatotic hepatocytes to hypoxia/reoxygenation stress is reversed by a novel defatting protocol.

Authors:  Nir I Nativ; Gabriel Yarmush; Ashley So; Jeffery Barminko; Timothy J Maguire; Rene Schloss; Francois Berthiaume; Martin L Yarmush
Journal:  Liver Transpl       Date:  2014-07-02       Impact factor: 5.799

3.  Recovery of the Cholangiocytes After Ischemia and Reperfusion Injury: Ultra-Structural, Hystological and Molecular Assessment in Rats.

Authors:  Thiago P A Aloia; Bruno Cogliati; Janaina M Monteiro; Anna C K Goldberg; Paolo R de Oliveira Salvalaggio
Journal:  J Clin Exp Hepatol       Date:  2018-02-11

4.  Decreased apoptosis in fatty livers submitted to subnormothermic machine-perfusion respect to cold storage.

Authors:  E Boncompagni; E Gini; A Ferrigno; G Milanesi; E Gringeri; S Barni; U Cillo; M Vairetti; I Freitas
Journal:  Eur J Histochem       Date:  2011-11-18       Impact factor: 3.188

5.  Metabolic Flux Distribution during Defatting of Steatotic Human Hepatoma (HepG2) Cells.

Authors:  Gabriel Yarmush; Lucas Santos; Joshua Yarmush; Srivathsan Koundinyan; Mubasher Saleem; Nir I Nativ; Rene S Schloss; Martin L Yarmush; Timothy J Maguire; Francois Berthiaume
Journal:  Metabolites       Date:  2016-01-04

6.  Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers.

Authors:  Sebastian Pratschke; Hannah Arnold; Alfred Zollner; Michael Heise; Andreas Pascher; Peter Schemmer; Marcus N Scherer; Andreas Bauer; Karl-Walter Jauch; Jens Werner; Markus Guba; Martin K Angele
Journal:  Transplant Direct       Date:  2016-05-04

7.  Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis.

Authors:  Sharma Love; Malik A Mudasir; Subhash C Bhardwaj; Gurdarshan Singh; Sheikh A Tasduq
Journal:  Oncotarget       Date:  2017-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.